49 results about "Molecular type" patented technology

The invention discloses the application of ionic type cyclodextrin derivative in preparation of medicine preparation for iontophoresis transdermal administration. The ionic type cyclodextrin derivative comprises one or two of cationic cyclodextrin derivative and anionic cyclodextrin derivative; the medicine is selected from one or more of molecular type medicine, charged medicine with the dissolubility less than 1mg/ml, faintly acid charged medicine with the dissociation constant p Ka larger than 4, or alkalescent charged medicine with the dissociation constant p Ka less than 4. The ionic type cyclodextrin derivative applied to the iontophoresis transdermal administration improves the transdermal penetration rate of the molecular type medicinem and the charged medicine with low dissolubility or degree of dissociation.

The invention discloses a neoantigen prediction method and device based on next-generation sequencing and a storage medium. The method comprises the following steps: obtaining genome sequencing data of a tumor sample and a normal sample, and tumor transcriptome sequencing data; carrying out mutation detection on the genome sequencing data to obtain point mutation and insertion and deletion mutation, and carrying out fusion gene mutation detection on the tumor transcriptome sequencing data to obtain fusion gene mutation; detecting the type of an HLA molecule to obtain an HLA molecule type result, matched with the normal sample, of the HLA molecule of the tumor sample; carrying out annotation from gene mutation to amino acid mutation on the point mutation, the insertion and deletion mutationand the fusion gene mutation; predicting peptide fragments subjected to point mutation, insertion and deletion mutation and fusion gene mutation to obtain corresponding mutation prediction peptide fragments; and inputting the mutation prediction peptide fragments and the HLA molecule type result into a neoantigen prediction model, and performing scoring and sorting through the neoantigen prediction model to obtain a neoantigen prediction result. High-quality neoantigen can be accurately obtained from the sequencing data.

The invention belongs to the field of medicinal chemistry, and in particular relates to fluoroquinolone derivatives and an application thereof. The compounds shown in a formula (I) are obtained by structural modification of fluoroquinolone medicines. The compounds provided by the invention can not only treat the infection caused by mycobacterium tuberculosis and common bacteria, but also can has activity inhibition effects on bacterial persister, citrus pathogenic bacteria, nicotinamide N-methyltransferase (NNMT) and interleukin IL-17 PPI; and the compounds have a simple and easy preparation process and mild conditions, a plurality of the compounds with enhanced antibacterial activity, improved water solubility and reduced toxic and side effects are obtained, and the compounds are expectedto reduce the dosage, shorten the treatment cycle and improve patient compliance, thereby providing novel molecular types and research ideas for medicines of tuberculosis and other diseases.

The invention pertains to biological resources and environmental technology, in particular to a marine caphalopoda animal I collagen protein product and the preparation method thereof. The invention discloses the marine caphalopoda animal collagen protein, the collagen protein is extracted from the skin of marine caphalopoda animals, the collagen protein is white or white with the light brown and is the I type collagen protein, the molecular type is (Alpha 1)2Alpha2 type, the molecular weight of the main peptide chain is 300 to 330KD, the intrinsic viscosity is 12 to 18dL/g, the denatured temperature is 15 to 30 DEG C, and every 1000 amino acid residues contain 280 to 330 parts of glycine, 80 to 90 parts of proline and 60 to 70 parts of hydroxyproline respectively. The preparation method takes squid skin which is one of the processing waste of the seafood as raw material for preparing the I type collagen protein; an edible biochemical reagent, mild preparation conditions and simple physical method are adopted for carrying out the extraction of the collagen protein in the squid skin; the obtained collagen protein product dose not have the residue problem of the toxic and harmful reagents, which has very high safety; therefore, in addition to the general usages of the collagen protein, the marine caphalopoda animal I collagen protein product can also be directly applied in the industries of general foods, special foods, functional foods and biomedicine; the usage of the method for preparing the collagen protein is environmental-friendly, which does not discharge toxic and harmful substances to the environment and can avoid the new pollution to the environment of certain preparation methods.

The invention provides a tumor molecular typing method and device, terminal equipment and a readable storage medium, and the method comprises the following steps: obtaining sequencing data of a plurality of tumor tissue samples, and calculating a copy number value; screening mutated genes in each tumor tissue sample; performing unsupervised clustering on the mutated genes to obtain a plurality of sample categories; screening genes with significant gene copy number variation among samples of each sample category, and performing unsupervised clustering to obtain a plurality of gene categories; calculating a first principal component based on the copy number variation, and determining the influence of the first principal component on the prognosis of the patient through regression analysis; and calculating copy number variation scores of the tumor tissue samples according to the influence of the first principal component on the prognosis of the patient, and classifying the samples of the sample categories according to the copy number variation scores to complete the molecular typing of the tumor. Molecular typing is carried out based on copy number variation of each gene, the resolution ratio is high, typing is accurate, and prognosis of tumor patients with different molecular types can be remarkably distinguished.

The invention is especially related to fixed phase of reversed phase chromatography (FPRPC) in macromolecule type of a series of different chemical constitution, and preparation method. Possessing macromolecule micro beads in regular spherical porous type, the disclosed FPRPC in macromolecule type possesses basic property of FPRPC. Using the disclosed FPRPC to carry out verification of chromatographic separation indicates that when macromolecule micro beads in porous type acts as FPRPC, pore structure is steady; under condition of compression elution, micro beads does not break up; adsorption-desorption procedure is quick; comparing with chemical bond silicon ball fixed phase in same granularity, FPRPC possesses closed column performance and closed separation. The disclosed FPRPC is applicable to separating and purifying medical bulk drug, and natural drug as well as applicable to enriching and preparing trace quantity substance in biologic and samples.

The invention discloses a method used for increasing sewage processing biomembrane formation speed and stability, and belongs to the technical field of sewage processing. According to the method, extraction and concentration of an active sludge sample in aerobic or anaerobic biomembrane sewage processing technology are carried out, ultra high performance liquid chromatography tandem electro-sprayion source analysis is adopted in analysis of AHL quorum sensing signals of the active sludge sample, quantitative calculation is carried out to determine AHL signal molecular type and using amount, and at last, exogenous AHLs signal molecules are added into aerobic or anaerobic biomembrane sewage processing technology based on the determined type and using amount, and synchronous nitrogen and phosphorus removal is realized. According to the method, analysis on flora AHL signal in biomembrane formation process is adopted, biomembrane formation speed is accelerated, and at the same time, the stability of the formed biomembrane is increased greatly. The method is capable of solving problems in the prior art that biomembrane formation early stage system operation is not stable, and biofilm culturing time is long. The method is adopted in regulation and control of biomembrane sewage processing technology starting phase, so that cost is reduced greatly.

The invention relates to a Python-based ReaxFF force field calculation result data processing method and belongs to the technical field of chemical molecular reaction kinetics. The method comprises steps of step 1, reading and integrating data of a molecular type information specis file; step 2, performing molecular classification of the integrated molecular information output.txt file; and 3, calculating the molecular weight of each product to obtain the molecular mass percentage of each product. The processing method is advantaged in that various data file types generated by simulation can be efficiently and conveniently read, and the time and steps consumed by the data file in format transfer are reduced; the method can conclude molecular types of diversified simulation products, can obtain change of various products along with the time, and provides convenience for the reaction molecular dynamics simulation to explore the pyrolysis combustion micromechanisms under various working conditions and clarify the change rule of products.

The invention provides a method and a system for detecting HLA (human leukocyte antigen) heterozygosity deficiency. The method comprises the following steps: data acquisition: acquiring sequencing data of a tumor sample and a control sample; hLA typing detection: detecting HLA molecular types of the tumor sample and the contrast sample; HLA allele imbalance detection: comparing the sequencing data with an HLA typing result to obtain an HLA allele imbalance detection result; copy number variation detection: performing copy number variation detection on all the target areas to obtain a copy number variation detection result of the HLA gene loci; and HLA heterozygosity deletion judgment: judging whether HLA heterozygosity deletion exists or not according to an HLA allele imbalance detection result and a copy number variation detection result. According to the invention, the sequence information on the HLA gene is used independently, and the sequence information near the HLA gene is also combined, so that an accurate HLA LOH result is obtained.

The invention relates to acrylic macromolecular surfactant and a method for making the porous resin of the same, belonging to the organic macromolecular compound field. The acrylic macromolecular surfactant comprises 93 to 97 percent of acrylic substance, 3 to 7 percent of vinyl ion reagent and 0.5 to 1 percent of initiator. The substances are added in a reactor containing an amount of water, and are reacted at a temperature controlled between 57 and 80 DEG C for 6 to 24 hours; then, the reactants undergo acetone deposition, ether scrubbing and deposition and vacuum drying. The porous resin is made through adopting the following steps that: the acrylic macromolecular surfactant, monomer, initiator and a crosslinking agent are added in water, cyclohexane or the mixed solution of water and cyclohexane; and round porous resin is made by means of emulsion polymerization under the action of the initiator. The method makes the porous resin by means of the acrylic macromolecular surfactant, wherein the surfactant has excellent performances and full emulsification; and the porous resin is round in shape with the diameter ranging between 50 and 500 micron. The porous resin made by the method contains active epoxy group, and can be used in the fields of enzyme immobilization, antibody adsorption and purification and blood pathogen or toxin cleaning, etc.

The invention discloses application of an SRGN gene and polypeptide thereof in serving as a detection marker for breast cancer molecular typing, in particular to application of the SRGN gene and the polypeptide thereof in serving as a serum marker for detecting a triple-negative breast cancer or in preparation of a detection reagent for the triple-negative breast cancer, and provides a novel breast cancer serum marker, that is, the SRGN gene and the polypeptide thereof. It is proved that expression of the SRGN gene in breast cancer serum is enhanced, and expression of the SRGN gene in serum of a triple-negative breast cancer patient is mainly and significantly increased compared with expression of the SRGN gene in serum of a breast cancer patient with the other molecular types. Accordingly, not only is a new target supplied to breast cancer serology detection, but also new data and a quick serology detection method are supplied to breast cancer molecular typing; a new chemical entity is designed at the gene level and the protein level by taking the gene as the target, breast cancer molecular typing can be quickly, conveniently and effectively performed, and therefore the breast cancer treatment effect is improved.

The invention discloses a construction method of a molecular prediction model, which is suitable for being executed in computing equipment, a feature type set, a feature engineering set and a prediction model set are stored in the computing equipment, the method comprises the following steps: collecting a plurality of pieces of molecular data of a specific molecular type, and the molecular data comprises performance data and at least one kind of feature data; one or more feature types, feature engineering and prediction models are selected from the feature type set, the feature engineering setand the prediction model set for traversal combination, and multiple combination modes are obtained; training each combination mode in combination with the plurality of pieces of molecular data and the feature type, the feature engineering and the prediction model in each combination mode to obtain a trained model and a model evaluation index; and selecting an optimal combination mode of the feature type, the feature engineering and the prediction model according to the model evaluation indexes to predict the properties of the same type of molecules. A computing device adapted to perform themethod is also disclosed.

The invention belongs to the technical field of biological medicines, particularly relates to application of protein/gene IFI30 related to breast cancer occurrence and development, and particularly provides application of the protein/gene IFI30 related to breast cancer occurrence and development, especially application value of the protein/gene IFI30 as a breast cancer molecular typing marker andapplication of the protein/gene IFI30 in preparation of a breast cancer molecular typing kit. The invention also provides a method for screening potential drugs for treating breast cancer. Whether thecandidate is a potential drug for treating breast cancer or not is judged by adjusting the expression level of the biomarker.

This invention provides a method for identifying one or more complexes from a library of complexes, wherein said complex or complexes are selected for their ability to perform a preselected or desired function on a target molecule or by having a pre-selected structure, each complex being designated a morphatide, said method comprising: (a) preparing a library of morphatides, comprised of: (i) a scaffolding component selected from the group consisting of nucleic acid, nucleic acid like molecule or nucleic acid analog having one or more regions of randomized sequence; (ii) one or more linker components; and (iii) one or more agent molecules or type of agent molecules, linked to the scaffolding component by one or more type of linker components; and (b)screening the library of morphatides prepared in step (a) by contacting, binding, or associating the morphatides with one or more suitable target molecules upon which a morphatide performs a preselected or desired function or to which a morphatide binds or associates through a pre-selected structure of said morphatide under conditions permitting said morphatide to perform said preselected or desired function on said target molecules or permitting said morphatide to bind or associate with said target molecules through the preselected structure; (c) separating the morphatides performing the preselected or desired function or binding or associating through the preselected structure, from the library of morphatides and target molecules; thereby identifying one or more complexes from a library of complexes, wherein said complex or complexes are selected for their ability to perform a preselected or desired function on a target molecule or by having a pre-selected structure.

Microplates or microstrips having wells with extended length to receive immunosorbent elements protruding from a rod at the same modular distance of wells arranged in standard microstrips or microplates and methods of use are provided. A solid phase is constituted by the extended wells, each of which immobilize a different type of cell or molecule in the sample; the other solid phase is constituted by immunosorbent elements protruding from a rod, each of which has been previously coated with one of the same markers to be detected in the sample. Ligands for markers to be detected are added in a liquid phase to the wells; allowing the ligands competitively bind to the immunosorbent elements, inversely proportional to the quantity of the markers of each type of cell or molecule immobilized on the proper extended well. These ligands are simultaneously quantifiable by an immunoenzymatic assay using chromogenic substrate and a spectrophotometer.

The invention relates to the technical field of water-based adhesives, in particular to a water-based adhesive for dry-type composite of plastic films and a preparation method thereof, and the water-based adhesive is prepared from the following components in parts by weight: 60-80 parts of deionized water, 0.5-1.0 part of a buffering agent, 0.8-1.2 parts of a persulfate oxidizing agent, 0.5-1.0 part of an anionic polymerizable emulsifier, 85-100 parts of a conventional acrylate monomer mixture, 7-13 parts of a heteroalicyclic acrylate monomer, 0.65-1.3 parts of a high-molecular type reducing agent, 0.5-1.0 part of a fine particle size emulsifier, 1.2-1.5 parts of a wetting agent and 0.5-0.8 part of a defoaming agent through a specific process. The water-based adhesive is more similar to asolvent-type polyurethane adhesive in the performance, is strong in plastic film adhesive force, good in temperature resistance and water resistance, and high in coating and drying speed, the coating4-cup viscosity is 12-18 seconds, and the solid content reaches 55-60%.

The invention discloses a method for preparing an amphoteric macromolecular surfactant with green and environment-friendly production process which is industrialized easily and can promote aging of sizing agent for papermaking. A monomer (a), a monomer (d) and a part of a monomer b are added in a reaction vessel accommodating solvent. Acid is used for adjusting PH value before the monomers are added or after the monomers are mixed. A reaction vessel is displaced with an inert gas before the reaction vessel is heated up to the temperature ranging from 40 DEG C to 95 DEG C. The monomer (c) and the remaining monomer (b) are added at a uniform speed while the mixture is stirred, and a primer is compounded. While the monomers are added, the temperature of the reaction vessel is controlled between 60 DEG C to 130 DEG C. After the primer is completed, the primer is aged for 0 to 120 minutes at the temperature of polymerization, and the temperature is reduced below 10 DEG C to 80 DEG C. PH value is adjusted. After a bacteria inhibitor is homogenized, the finished product is got. With excellent effects, low price, improved sizing speed, reduced dose level of the sizing agent, no weakening on the effect of a fluorescer, the product is innocuous to the ecological environment, and can be degraded easily in nature without increasing the difficulty to disintegrate paper.

The present invention provides a method for specific sorting of CTC in serum of biliary tract tumors. An appropriate amount of peripheral blood from patients with biliary tract tumors is taken and placed in anticoagulation centrifuge tubes and whole blood samples are mixed evenly; the collected blood samples are sequentially subjected to sample processing of plasma protein and plasma nucleic acidremoval, red blood cell removal, layered centrifugation and white blood cell removal; an HSPG antibody or a SDC1 subtype antibody or a SDC2 subtype antibody or a GPC1 subtype antibody or a GPC3 subtype antibody is used to combine with immunomagnetic beads to capture HSPG positive or SDC1 positive or SDC2 positive or GPC1 positive or GPC3 positive CTC. HSPG is used as a relatively specific functional tumor molecular marker for CTC sorting of gallbladder cancer and cholangiocarcinoma, thereby improving sorting efficiency of biliary tract tumor CTC, a set of HSPG-based CTC molecular typing scoring system is established, the high-specificity and high-sensitivity detection method for the biliary tract tumors is otbained, and based on the high-efficiency sorting of the biliary tract tumor CTC, downstream RNA-seq and gene NGS detection is conducted to obtain tumor-specific molecular information to improve specificity.